BioMarin Clears Final French FDI Hurdle for Amicus Merger, Deal Expected to Close April 27
BMRN is trading near its 52-week low of $50.76 (6.2% above the low).
Summary
BioMarin Pharmaceutical Inc. has announced it received final foreign direct investment clearance from the French Ministry of Economics and Finance for its merger with Amicus Therapeutics. This clearance satisfies the final pre-closing condition, and the merger is now expected to close on April 27, 2026. The $4.8 billion acquisition of Amicus was a major event detailed in BioMarin's 2025 annual report, and this update removes a significant regulatory hurdle, de-risking the transaction. This is a material development for BioMarin, confirming the imminent completion of a major strategic acquisition. Investors will now focus on the official closing of the deal and any subsequent integration plans or updated financial guidance.
At the time of this announcement, BMRN was trading at $53.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.4B. The 52-week trading range was $50.76 to $66.28. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.